THE MASTHEAD / WHO WE ARE
A reading room, not a clinic.
What this project is, what it is not, and how it handles the published record on semaglutide.
What this project is
Medicinal Semaglutide is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on semaglutide. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
We built this as a dark reading room — a quiet place to read a remarkably deep clinical record one trial at a time, led by the image that drew us to it: the liver, the organ the modern diet wears down first, and the peptide that a 2025 trial showed could help mend it.
About the name
The word "medicinal" in our name is editorial framing — a position we occupy relative to the literature, the stance of a reading room oriented toward an approved medicine and its evidence. It is not a claim that this site offers medicine, treatment, consultation, or a prescription. We are readers of the record, not providers of care.
Semaglutide is, in fact, an approved prescription medicine when prescribed and dispensed as the manufactured product. That is precisely why we treat it as a literature to be summarized rather than a compound to be cautioned against. Where the evidence is strong, we say so plainly; where it is uncertain, we say that too.
How we handle the evidence
Our rules are simple and strict. Every quantitative claim is tied to a numbered, verifiable study. We name doses only as they were documented in trials and labeling, in the third person, and we never recommend a dose for any individual. We keep what people report — anecdotal, community-sourced experience — visibly separate from what controlled trials measured, because they are not the same kind of evidence.
We use only generic, non-proprietary drug names. We do not link to vendors, we do not source products, and we take no position on where or whether anyone should obtain a medicine. When the record changes — as it did when the liver, heart, and kidney trials read out — we update the reading, not the marketing.